China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store – L.L.C – O.P.C (Pharmalink), a prominent pharmaceutical company based in the United Arab Emirates (UAE), concerning its anti-PD-L1 monoclonal antibody (mAb) sugemalimab.
Commercial Rights and Deal Terms
Under the agreement, Pharmalink will acquire the commercial rights to sugemalimab in the Middle East and North Africa (MENA) Region, including countries such as Saudi Arabia, UAE, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco, Libya, and South Africa. CStone will receive an undisclosed amount of upfront payments, regulatory milestone payments, and net sales royalties from Pharmalink, who will handle the regulatory activities and commercialization of sugemalimab in the specified regions. CStone will be responsible for the supply of the drug.
Global Commercialization and Expansion Plans
This collaboration follows a significant international partnership for the global commercialization of sugemalimab. In May of this year, CStone entered into a partnership with Ewopharma, granting the European firm commercialization rights to the drug in Switzerland and the 18 Central and Eastern European Countries (CEECs). CStone anticipates further commercial collaborations in Western Europe, Latin America, Southeast Asia, and Canada in the near term.
Sugemalimab’s Approvals and Indications
Sugemalimab was first approved in China in December 2021 and has since received five indication approvals, including stage III and IV non-small cell lung cancer (NSCLC), extranodal NK/T cell lymphoma, esophageal squamous cell carcinoma, and gastric cancer. The drug is also registered in the European Union, European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway), and the United Kingdom.-Fineline Info & Tech
Leave a Reply